PERSEE
What it tests: Pembrolizumab with vs without platinum chemo as first-line in advanced NSCLC with PD-L1 ≥50%
4Sight: PERSEE
All ESMO 2026 4Sights
In brief
OncoAlert 4Sight, #ESMO2026
Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%: PERSEE Phase 3 Trial (GFPC 01-2020)
Phase 3, open-label (n=321): pembrolizumab + platinum-based chemotherapy vs pembrolizumab alone, first-line advanced NSCLC with PD-L1 ≥50%. Primary endpoint: PFS by blinded central review.
Median PFS 16.1 vs 6.9 mo; HR 0.56 (0.43–0.74); p<0.001
Median OS 50.2 vs 29.9 mo; HR 0.77 (0.57–1.05); ORR 77.5% vs 50.3%
Grade ≥3 TRAEs 53.8% vs 19.3%
Pembrolizumab-chemotherapy significantly improved PFS vs pembrolizumab monotherapy and may help refine treatment selection.
Chantal Decroisette
Renaud Descourt · Christos Chouaid · Maurice Pérol · Benjamin Besse · Laurent Greillier · Olivier Bylicki · Charles Ricordel · Florian Guisier · Radj Gervais · Roland Schott · Jean-Bernard Auliac · Gilles Robinet